P&G’s Q3: Negative Pricing, ‘Change In Tone’ Have Analysts Spooked
This article was originally published in The Rose Sheet
Executive Summary
Firm’s slowing organic growth and negative pricing impacts in the third quarter reflect much-talked-about pressures in health and beauty care. However, the scope of the challenges is becoming clearer, and analysts are questioning whether P&G’s “not business as usual” response will be enough.
You may also be interested in...
P&G’s SK-II Jockeying For Top Spot In Asian Prestige Skin Care
P&G’s super-premium SK-II skin-care brand is growing at a 20% clip and accumulating new users just as quickly, thanks in large part to its “Change Destiny” campaign, CFO Jon Moeller said at the Deutsche Bank Global Consumer Conference June 14. The firm is also reaping the benefits of Gillette razor investments and price cuts, but threats remain.
IFF’s $7.1bn Frutarom Buy Shows Market Shifts Rippling Up The Supply Chain
The flavors and fragrances firm’s largest acquisition to date speaks volumes about prevailing market winds, providing IFF with access to smaller customers and Frutarom’s extensive natural capabilities. The deal closely follows rival Givaudan’s opening move in March to acquire Naturex.
P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint
P&G’s planned purchase of Merck KGaA’s consumer health care business will grow its personal health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor framed the acquisition as another step in the firm's ongoing portfolio shakeup.